<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225040</url>
  </required_header>
  <id_info>
    <org_study_id>AAAE5304</org_study_id>
    <nct_id>NCT03225040</nct_id>
  </id_info>
  <brief_title>Bone MicroArchitecture in Acromegaly</brief_title>
  <official_title>Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a cross-sectional study of bone density, bone&#xD;
      microarchitecture, vertebral fractures and trabecular bone score in 25 patients with&#xD;
      acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least&#xD;
      1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to&#xD;
      describe the bone architecture and associated biochemical indices of bone turnover and&#xD;
      metabolism in patients with active acromegaly and how these are altered with treatment of the&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growth hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) are important regulators of bone&#xD;
      modeling and remodeling, fundamental to maintenance of normal skeletal integrity. In&#xD;
      acromegaly, a disease characterized by longstanding exposure to excess GH and IGF-1, these&#xD;
      hormones induce marked skeletal changes. Most dual energy X-ray absorptiometry (DXA) studies&#xD;
      report that bone mineral density (BMD) is normal in acromegaly. Despite this, however, there&#xD;
      is mounting evidence that bone health is adversely affected in patients with both active and&#xD;
      successfully treated acromegaly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2016</start_date>
  <completion_date type="Actual">December 21, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric bone mineral density of radius (vBMD)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>Volumetric bone mineral density of radius (vBMD) measured by high resolution peripheral quantitative computed tomography (HRpQCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trabecular number of radius (TbN)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Thickness of radius (Tb.Th)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular separation of radius (Tb.Sp)</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical density of radius</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical thickness of radius</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>HRpQCT determined bone microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areal bone mineral density (aBMD) of lumbar sacral spine</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>Areal bone mineral density of lumbar sacral spine determined by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular bone score of LS spine</measure>
    <time_frame>Measured once at one study visit</time_frame>
    <description>Trabecular bone score of lumbar sacral (LS) spine determined by DXA</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">77</enrollment>
  <condition>Acromegaly</condition>
  <condition>Osteoporosis Risk</condition>
  <arm_group>
    <arm_group_label>Acromegaly patients on pegvisomant</arm_group_label>
    <description>25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegvisomant</intervention_name>
    <description>Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.</description>
    <arm_group_label>Acromegaly patients on pegvisomant</arm_group_label>
    <other_name>Somavert</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1&#xD;
        year will be studied.&#xD;
&#xD;
        Patients will be on stable doses of any pituitary hormone supplements for 3 months prior to&#xD;
        study entry including gonadal steroid replacement for men or premenopausal women.&#xD;
        Hypogonadal men and premenopausal women will be replaced with clinically appropriate sex&#xD;
        steroid replacement. Subjects will be 50% females.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with acromegaly&#xD;
&#xD;
          -  On pegvisomant therapy with a normal IGF-1 level for at least 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancy (except cured basal, squamous cell skin carcinoma or other cured cancers&#xD;
             free from recurrence &gt; 3 years)&#xD;
&#xD;
          -  Pregnancy or lactation within last 12 months&#xD;
&#xD;
          -  Untreated primary hyperparathyroidism, hyper- or hypothyroidism&#xD;
&#xD;
          -  Cushing's syndrome&#xD;
&#xD;
          -  Prolactin-secreting pituitary adenoma&#xD;
&#xD;
          -  GH deficiency&#xD;
&#xD;
          -  On current drug therapy for osteoporosis&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Current or past use of glucocorticoids (more than physiologic dose), anticonvulsants,&#xD;
             anticoagulants, methotrexate, aromatase inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Freda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuroendocrine Unit and Pituitary Center, Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Pamela U. Freda</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Pegvisomant</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

